- Home
- SLS vs EDIT Comparison
SLS vs EDIT Comparison
Compare SLS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- EDIT
- Stock Information
- Founded
- SLS 2012
- EDIT 2013
- Country
- SLS United States
- EDIT United States
- Employees
- SLS N/A
- EDIT N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLS Health Care
- EDIT Health Care
- Exchange
- SLS Nasdaq
- EDIT Nasdaq
- Market Cap
- SLS 169.6M
- EDIT 179.1M
- IPO Year
- SLS N/A
- EDIT 2016
- Fundamental
- Price
- SLS $1.85
- EDIT $2.88
- Analyst Decision
- SLS
- EDIT Buy
- Analyst Count
- SLS 0
- EDIT 12
- Target Price
- SLS N/A
- EDIT $6.20
- AVG Volume (30 Days)
- SLS 3.6M
- EDIT 3.5M
- Earning Date
- SLS 08-12-2025
- EDIT 08-06-2025
- Dividend Yield
- SLS N/A
- EDIT N/A
- EPS Growth
- SLS N/A
- EDIT N/A
- EPS
- SLS N/A
- EDIT N/A
- Revenue
- SLS N/A
- EDIT $35,837,000.00
- Revenue This Year
- SLS N/A
- EDIT N/A
- Revenue Next Year
- SLS N/A
- EDIT N/A
- P/E Ratio
- SLS N/A
- EDIT N/A
- Revenue Growth
- SLS N/A
- EDIT N/A
- 52 Week Low
- SLS $0.77
- EDIT $0.91
- 52 Week High
- SLS $2.27
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- SLS 52.48
- EDIT 74.64
- Support Level
- SLS $1.88
- EDIT $2.48
- Resistance Level
- SLS $2.27
- EDIT $3.24
- Average True Range (ATR)
- SLS 0.17
- EDIT 0.25
- MACD
- SLS -0.00
- EDIT 0.07
- Stochastic Oscillator
- SLS 52.60
- EDIT 84.84
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.